Skip to main content

Table 3 Prediction of stability at 6 months from administration of anti-fibrotic drugs in univariate analysis

From: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis

Variable

OR (95% CI)

P-value

Sex, Male

0.64 (0.15–2.83)

0.55

Age

1.05 (0.96–1.14)

0.24

Smokers

1.27 (0.33–4.96)

0.72

Pack-years smoking

1.01 (0.99–1.03)

0.59

BMI

0.89 (0.74–1.08)

0.22

% FVC (%)

1.01 (0.98–1.04)

0.61

% DLco (%)

1.00 (0.95–1.04)

0.83

PaO2 at rest (Torr)

1.01 (0.94–1.09)

0.71

Minimum SpO2 during 6MWT (%)

1.06 (0.93–1.21)

0.37

6MWT Distance (m)

1.00 (0.99–1.01)

0.80

SP-A (ng/mL)

0.99 (0.98–1.01)

0.30

SP-D (ng/mL)

1.00 (1.00–1.00)

0.64

KL-6 (U/mL)

1.00 (1.00–1.00)

0.65

Pirfenidone

2.01 (0.62–6.99)

0.23

Treatment history of anti-fibrotic drugs (n)

0.69 (0.14–3.53)

0.66

Change in SP-A in 3 months (%)

0.89 (0.82–0.96)

< 0.01

Change in SP-D in 3 months (%)

0.98 (0.96–1.00)

0.12

Change in KL-6 in 3 months (%)

0.96 (0.92–0.99)

< 0.01

Change in SP-A in 6 months (%)

0.89 (0.84–0.95)

< 0.01

Change in SP-D in 6 months (%)

0.95 (0.92–0.99)

< 0.01

Change in KL-6 in 6 months (%)

0.93 (0.89–0.97)

< 0.01

  1. OR odd’s ratio; BMI body mass index; FVC forced vital capacity; DLco diffusing capacity of the lung for carbon monoxide; PaO2 partial pressure of arterial oxygen; SpO2 arterial oxygen saturation measured by pulse oximetry; 6MWT 6 min-walk test; SP surfactant protein; KL-6 Krebs von den Lungen-6